Albireo Pharma (Albireo Pharma) Change In Inventory : $-3.10 Mil (TTM As of Sep. 2022)

View and export this data going back to 2007. Start your Free Trial

What is Albireo Pharma Change In Inventory?

Albireo Pharma's change in inventory for the quarter that ended in Sep. 2022 was $-1.20 Mil. It means Albireo Pharma's inventory increased by $1.20 Mil from Jun. 2022 to Sep. 2022 .

Albireo Pharma's change in inventory for the fiscal year that ended in Dec. 2021 was $-0.19 Mil. It means Albireo Pharma's inventory increased by $0.19 Mil from Dec. 2020 to Dec. 2021 .

Albireo Pharma's Total Inventories for the quarter that ended in Sep. 2022 was $3.15 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Albireo Pharma's Days Inventory for the quarter that ended in Sep. 2022 was 391.02.

Inventory Turnover measures how fast the company turns over its inventory within a year. Albireo Pharma's Inventory Turnover for the quarter that ended in Sep. 2022 was 0.23.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Albireo Pharma's Inventory-to-Revenue for the quarter that ended in Sep. 2022 was 0.27.

Albireo Pharma Change In Inventory Historical Data

The historical data trend for Albireo Pharma's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Albireo Pharma Change In Inventory Chart

Albireo Pharma Annual Data

Trend

Sep12

Sep13

Sep14

Sep15

Sep16

Dec17

Dec18

Dec19

Dec20

Dec21

Change In Inventory

Get a 7-Day Free Trial

-0.19

Albireo Pharma Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Change In Inventory	Get a 7-Day Free Trial															-	-	-1.63	-0.28	-1.20

Albireo Pharma Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.10 Mil.

Albireo Pharma (NAS:ALBO) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Albireo Pharma's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	2.6225	/	0.612	*	365 / 4
	=	391.02

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Albireo Pharma's Inventory Turnover for the quarter that ended in Sep. 2022 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0.612	/	2.6225
	=	0.23

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Albireo Pharma's Inventory to Revenue for the quarter that ended in Sep. 2022 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	2.6225	/	9.832
	=	0.27

Albireo Pharma Change In Inventory Related Terms

Thank you for viewing the detailed overview of Albireo Pharma's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Albireo Pharma (Albireo Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Albireo Pharma Inc (NAS:ALBO) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

N/A

Address

53 State Street, 19th Floor, Boston, MA, USA, 02109

Website

https://www.albireopharma.com

Albireo Pharma Inc is a commercial-stage biopharmaceutical company. It focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. The Company's product pipeline includes Bylvay, which is approved in the United States and Europe; elobixibat, which is approved in Japan for the treatment of chronic constipation; A3907, its Phase 1 lead candidate for the treatment of adult liver diseases; and A2342, it's a lead preclinical candidate for the treatment of adult viral and liver diseases.

Executives

Harford Simon N.r.	officer: CFO and Treasurer	AVON PRODUCTS, INC., 1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105
Pamela Stephenson	officer: Chief Commercial Officer	C/O ZYNERBA PHARMACEUTICALS, INC., 80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333
Martha J. Carter	officer: Chief Regulatory Officer	C/O AEGERION PHARMACEUTICALS, INC., 89 HEADQUARTERS PLAZA, SUITE 1212, MORRISTOWN NJ 07960
Jan Mattsson	officer: Chief Operating Officer	C/O ALBIREO PHARMA, INC., 50 MILK STREET, 16TH FLOOR, BOSTON MA 02109
Cooper Ronald Harold Wilfred	director, officer: President and CEO	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Michelle Graham	officer: Chief Human Resources Officer	10000 WEHRLE DRIVE, CLARENCE NY 14031
Jason Duncan	officer: General Counsel	C/O ALBIREO PHARMA, INC., 10 POST OFFICE SQUARE, SUITE 502 SOUTH, BOSTON MA 02109
Paul Streck	officer: Chief Medical Officer	10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Craig C. Hopkinson	director	852 WINTER STREET, WALTHAM MA 02451
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Susan Alesina	director	C/O ALBIREO PHARMA, INC., 53 STATE STREET, 19TH FLOOR, BOSTON MA 02109
Habib J Dable	director	C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Patrick Taylor Horn	officer: Chief Medical Officer	C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
Perceptive Advisors Llc	10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003